autologous ny-eso-1-specific cd8-positive t lymphocytes
Cell therapyexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2014 (NCT02059850)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cancer/testis antigen 1Immunity, passive
Cancer/testis antigen 1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous ny-eso-1-specific cd8-positive t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03691376 | Phase 1 | Oct 1, 2018 | State University of New York, Buffalo |
| NCT03450122 | Phase 1 | Sep 13, 2018 | Immune Design, University of Texas at Houston |
| NCT02319824 | Phase 1 | Jan 1, 2015 | National Cancer Institute (NCI), University of Washington |
| NCT02059850 | Phase 1 | Jul 1, 2014 | National Cancer Institute (NCI), University of Washington |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2014 |
| University of Washington | Academic/Hospital | 2 | 2 | 1 | 2014 |
| Immune Design | For profit | 1 | 0 | 1 | 2018 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2018 |
5 organizations
Page 1 / 1